IL191810A - Dll4 antagonists and vegf inhibitor and their use in tumor development or growth methods - Google Patents

Dll4 antagonists and vegf inhibitor and their use in tumor development or growth methods

Info

Publication number
IL191810A
IL191810A IL191810A IL19181008A IL191810A IL 191810 A IL191810 A IL 191810A IL 191810 A IL191810 A IL 191810A IL 19181008 A IL19181008 A IL 19181008A IL 191810 A IL191810 A IL 191810A
Authority
IL
Israel
Prior art keywords
growth
methods
inhibiting tumor
tumor development
vegf inhibitor
Prior art date
Application number
IL191810A
Other languages
English (en)
Hebrew (he)
Other versions
IL191810A0 (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38163537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL191810(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL191810A0 publication Critical patent/IL191810A0/en
Publication of IL191810A publication Critical patent/IL191810A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL191810A 2005-12-16 2008-05-29 Dll4 antagonists and vegf inhibitor and their use in tumor development or growth methods IL191810A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75117305P 2005-12-16 2005-12-16
US77127606P 2006-02-08 2006-02-08
US78845606P 2006-03-31 2006-03-31
US83054306P 2006-07-12 2006-07-12
PCT/US2006/047848 WO2007070671A2 (en) 2005-12-16 2006-12-15 Therapeutic methods for inhibiting tumor growth with dll4 antagonists

Publications (2)

Publication Number Publication Date
IL191810A0 IL191810A0 (en) 2009-02-11
IL191810A true IL191810A (en) 2017-11-30

Family

ID=38163537

Family Applications (1)

Application Number Title Priority Date Filing Date
IL191810A IL191810A (en) 2005-12-16 2008-05-29 Dll4 antagonists and vegf inhibitor and their use in tumor development or growth methods

Country Status (12)

Country Link
US (1) US20080107648A1 (enExample)
EP (1) EP1962895B2 (enExample)
JP (1) JP5489465B2 (enExample)
AU (1) AU2006326417B2 (enExample)
CA (1) CA2630839C (enExample)
DK (1) DK1962895T3 (enExample)
ES (1) ES2400666T5 (enExample)
IL (1) IL191810A (enExample)
NZ (1) NZ568739A (enExample)
PL (1) PL1962895T3 (enExample)
PT (1) PT1962895E (enExample)
WO (1) WO2007070671A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
US20080014196A1 (en) * 2006-06-06 2008-01-17 Genentech, Inc. Compositions and methods for modulating vascular development
CA2654000A1 (en) * 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
US7750124B2 (en) * 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
CL2007002989A1 (es) 2006-10-19 2008-05-16 Genentech Inc Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3.
AR063494A1 (es) * 2006-10-19 2009-01-28 Genentech Inc Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2008076960A2 (en) * 2006-12-18 2008-06-26 Genentech, Inc. Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EP2120996A2 (en) * 2006-12-20 2009-11-25 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US20100119526A1 (en) * 2007-01-26 2010-05-13 Bioinvent International Ab DLL4 Signaling Inhibitors and Uses Thereof
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
WO2009124931A2 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
US7544476B1 (en) * 2008-07-11 2009-06-09 Aveo Pharmaceuticals, Inc. Identifying cancers sensitive to treatment with inhibitors of notch signaling
MX2011002837A (es) * 2008-09-19 2011-07-29 Medimmune Llc Anticuerpos dirigidos al ligando tipo delta 4 (dll4) y usos de los mismos.
ES2541726T3 (es) * 2008-10-01 2015-07-23 F. Hoffmann-La Roche Ag Anticuerpos anti-Notch2 y métodos de uso
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
PE20121647A1 (es) 2009-08-29 2012-12-31 Abbvie Inc Proteinas terapeuticas de union a dll4
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
EP3485908B1 (en) * 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
WO2011068840A1 (en) * 2009-12-01 2011-06-09 Oncomed Pharmaceuticals, Inc. Methods for treating cancers comprising k-ras mutations
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
SG10201501562VA (en) 2010-03-02 2015-04-29 Abbvie Inc Therapeutic dll4 binding proteins
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
HRP20190044T1 (hr) 2011-09-23 2019-02-22 Oncomed Pharmaceuticals, Inc. Agensi koji vežu vegf/dll4 i njihove uporabe
JP2015532272A (ja) 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
AU2013337811A1 (en) 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
MX382902B (es) 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization
WO2023063842A1 (ru) * 2021-10-12 2023-04-20 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующая слитый белок
WO2024130165A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
ES2236634T3 (es) † 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
WO1998051799A1 (en) * 1997-05-14 1998-11-19 Asahi Kasei Kogyo Kabushiki Kaisha Novel differentiation inhibitor
CN1308347C (zh) † 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
JP4723140B2 (ja) † 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
JP2005526701A (ja) * 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
CA2469204A1 (en) * 2001-12-07 2003-06-19 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
EP1537145A1 (en) 2002-09-10 2005-06-08 Lorantis Limited Pharmaceutical compositions and medical treatments comprising notch ligand proteins
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
WO2007028110A2 (en) 2005-09-01 2007-03-08 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
US20080014196A1 (en) 2006-06-06 2008-01-17 Genentech, Inc. Compositions and methods for modulating vascular development
CA2654000A1 (en) † 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same

Also Published As

Publication number Publication date
US20080107648A1 (en) 2008-05-08
WO2007070671A2 (en) 2007-06-21
JP5489465B2 (ja) 2014-05-14
AU2006326417A1 (en) 2007-06-21
ES2400666T3 (es) 2013-04-11
NZ568739A (en) 2010-09-30
WO2007070671A3 (en) 2008-01-10
PL1962895T3 (pl) 2013-06-28
CA2630839A1 (en) 2007-06-21
EP1962895B2 (en) 2016-01-20
PT1962895E (pt) 2013-03-28
DK1962895T3 (da) 2013-03-04
EP1962895B1 (en) 2013-02-13
ES2400666T5 (es) 2016-03-10
EP1962895A2 (en) 2008-09-03
IL191810A0 (en) 2009-02-11
AU2006326417B2 (en) 2012-05-24
CA2630839C (en) 2017-01-17
JP2009519944A (ja) 2009-05-21

Similar Documents

Publication Publication Date Title
IL191810A (en) Dll4 antagonists and vegf inhibitor and their use in tumor development or growth methods
ZA200701635B (en) Quinazolinone derivatives and their use as B-Raf inhibitors
EP1742627A4 (en) PDE4B HEMMER AND ITS USE
ZA200701366B (en) Quinazolinone derivatives and their use as B-Raf inhibitors
IL182726A0 (en) 5-heteroaryl thiazoles and their use as p13k inhibitors
IL243669B (en) Sirna-type rtp801 inhibitors for use together with vegf inhibitors or vegf receptor 1 inhibitors
EP2076128A4 (en) PROTEIN CHINESE INHIBITOR AND ITS USE METHOD
ZA200801441B (en) p38MAP kinase inhibitors and methods for using the same
EP1812049A4 (en) KALLIKREIN INHIBITORS AND USES THEREOF
EP1794137A4 (en) SPECIFIC KINASE INHIBITORS
ZA200702855B (en) Cupredoxin derived transport agents and methods of use thereof
IL179398A0 (en) Dpp-ib inhibitors
EP2023874A4 (en) METHOD FOR IDENTIFYING ACTIVE SUBSTANCES AND THEIR USE FOR THE PREVENTION OF RESTENOSIS
IL207415A0 (en) Protein kinase inhibitors and use thereof
ZA201003420B (en) Protein kinase inhibitors and use thereof
HRP20130828T1 (en) Novel hydroxy-6-heroarylphenanthridines and their use as pde4 inhibitors
EP2097378A4 (en) NOVEL INHIBITORS OF SEH AND USE THEREOF
EP1922086A4 (en) TARGETED PROTEIN KINASE C HEMMER AND ITS USES
IL177709A0 (en) Caspase inhibitors and uses thereof
ZA200606070B (en) Substituted quinolines and their use as mycrobacterial inhibitors
PT1611890E (pt) Métodos para avaliação e tratamento do cancro
GB0421355D0 (en) Inhibitors
SI1962895T1 (sl) Terapevtska uporaba DII4 antagonista in VEGF inhibitorja za inhibiranje tumorske rasti
GB0405304D0 (en) Compounds and their use
GB0405306D0 (en) Compounds and their use

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees